S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in
NASDAQ:ATRA

Atara Biotherapeutics Stock Forecast, Price & News

$18.33
+0.06 (+0.33 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.40
Now: $18.33
$18.63
50-Day Range
$18.27
MA: $21.40
$26.23
52-Week Range
$4.52
Now: $18.33
$28.20
Volume642,694 shs
Average Volume910,202 shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.65
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and viral diseases, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; ATA230 for cytomegalovirus; ATA368 for HPV; ATA520 for Wilms Tumor 1; and ATA621 for BK and JCV. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was founded in 2012 and is headquartered in South San Francisco, California.
Atara Biotherapeutics logo

MarketRank

Overall MarketRank

1.56 out of 5 stars

Medical Sector

355th out of 1,926 stocks

Biological Products, Except Diagnostic Industry

42nd out of 177 stocks

Analyst Opinion: 4.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATRA
CUSIPN/A
Phone650-278-8930
Employees429

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.37 per share

Profitability

Net Income$-290,980,000.00

Miscellaneous

Market Cap$1.42 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$18.33
+0.06 (+0.33 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATRA News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions

How has Atara Biotherapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ATRA stock has increased by 84.0% and is now trading at $18.33.
View which stocks have been most impacted by COVID-19
.

Is Atara Biotherapeutics a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Atara Biotherapeutics stock.
View analyst ratings for Atara Biotherapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Atara Biotherapeutics?

Wall Street analysts have given Atara Biotherapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Atara Biotherapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Atara Biotherapeutics' CEO?

1,448 employees have rated Atara Biotherapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Atara Biotherapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Atara Biotherapeutics' next earnings date?

Atara Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Atara Biotherapeutics
.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) issued its earnings results on Saturday, November, 14th. The biotechnology company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.17.
View Atara Biotherapeutics' earnings history
.

What price target have analysts set for ATRA?

10 analysts have issued 1 year price objectives for Atara Biotherapeutics' stock. Their forecasts range from $14.00 to $78.00. On average, they anticipate Atara Biotherapeutics' share price to reach $34.25 in the next twelve months. This suggests a possible upside of 86.9% from the stock's current price.
View analysts' price targets for Atara Biotherapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Atara Biotherapeutics' key competitors?

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

Who are Atara Biotherapeutics' key executives?

Atara Biotherapeutics' management team includes the following people:
  • Dr. Pascal Touchon D.V.M., Pres, CEO & Director (Age 58, Pay $953.88k)
  • Mr. Utpal Koppikar, Chief Financial Officer (Age 50, Pay $596.38k)
  • Mr. Joseph Newell, Exec. VP & COO (Age 51, Pay $546.1k)
  • Eric Hyllengren, Head of Investor Relations & Fin.
  • Mr. Amar Murugan, Sr. VP & Gen. Counsel (Age 46)
  • Kerry Beth Daly, Head of Corp. Communications
  • Mr. Steve Bertram, Sr. VP & Chief People Officer
  • Dr. Manher Joshi, Chief Medical Officer
  • Dr. José Eduardo Vidal Ph.D., Head of Quality Assurance and Process Sciences
  • Mr. Tim Valko, Sr. VP of Global Manufacturing & Supply Chain

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%). Company insiders that own Atara Biotherapeutics stock include Christopher Haqq, Derrell Porter, Eric Dobmeier, Isaac E Ciechanover, Joe Newell, Joel S Marcus, Pascal Touchon and Utpal Koppikar.
View institutional ownership trends for Atara Biotherapeutics
.

Which institutional investors are selling Atara Biotherapeutics stock?

ATRA stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Joe Newell, Pascal Touchon, and Utpal Koppikar.
View insider buying and selling activity for Atara Biotherapeutics
or view top insider-selling stocks.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $18.33.

How big of a company is Atara Biotherapeutics?

Atara Biotherapeutics has a market capitalization of $1.42 billion. The biotechnology company earns $-290,980,000.00 in net income (profit) each year or ($5.67) on an earnings per share basis. Atara Biotherapeutics employs 429 workers across the globe.

What is Atara Biotherapeutics' official website?

The official website for Atara Biotherapeutics is www.atarabio.com.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.